HOME >> BIOLOGY >> NEWS
Blood markers may reflect newborns' potential of contracting HIV

Preventing HIV-infected pregnant women from transmitting the virus to their newborns has long been a major concern for obstetricians. As such, many doctors continue to debate the benefits of elective Caesarian section as a way to protect the infant.

In high-risk pregnancies, where the viral loads can't be suppressed with medication, delivering a baby by C-section directly from the protected, sterile environment of the amniotic sac can limit the risk of HIV transmission. But in lower-risk pregnancies, where antiretroviral medications keep the virus in check, the risk of transmitting HIV to a newborn is only about 1 percent to 2 percent.

A new study by researchers at Johns Hopkins and the National Institutes of Health demonstrates that uncomplicated labor and vaginal delivery does not stimulate the babies' immune systems. Results are scheduled to be presented Jan. 18 at the annual meeting of the Society for Maternal-Fetal Medicine in New Orleans.

A research team led by Hopkins obstetrician Helene Bernstein, M.D., Ph.D., studied lymphocytes from the umbilical cords of 23 babies born by vaginal delivery or elective C-section, as well as cells taken from eight babies born to mothers who had chorioamnionitis (a bacterial infection of the amniotic sac) or preterm labor.

None of the women had HIV. Checking for specific biochemical markers of white blood cell activation, they found the level of cell activity to be similar among babies born by either method. In addition, when HIV was introduced to these cells in the laboratory, there was no difference in their ability to be infected.

However, the babies born to mothers with chorioamnionitis or preterm labor did show activation of their white blood cells. When HIV was introduced to the white blood cells in the laboratory, there were more infections and the virus grew quickly, meaning that these infants could be at higher risk for HIV transmission if born to HIV-infected mothers with
'"/>

Contact: Karen Blum
kblum@jhmi.edu
410-955-1534
Johns Hopkins Medical Institutions
18-Jan-2002


Page: 1 2

Related biology news :

1. Blood pressure hormone may inhibit growth of lung cancer
2. Blood tests identify patients on dialysis at high risk for death from cardiovascular disease
3. Blood banking systems improving in China, more progress needed
4. Blood proteins tied to inflammation
5. Bloodworms way with copper likely provides paradigm for new materials
6. Blood stem cells carry targeted genes
7. Blood vessels trigger development of the pancreas
8. Blood vessels found to signal chain of destruction in bone diseases
9. Blood markers associated with autism and mental retardation
10. Blood test for diagnosing schizophrenia
11. Blood pressure-lowering DASH diet also reduces homocysteine

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/7/2016)... -- BioCatch , the global leader in behavioral biometrics, ... grew to over 40 granted and pending patents. ... , , The Company,s IP ... System, Device, and Method Estimating Force Applied to a Touch Surface, ... costly hardware components needed to estimate the force and pressure applied to ...
(Date:12/7/2016)... 2016   Veridium , a leader in ... new CEO James Stickland . Stickland, a ... experience, has served in senior executive roles for ... in expanding a pipeline of venture capital and ... recently served as managing director of U.K.-based fintech ...
(Date:12/6/2016)... , Dec. 6, 2016 Valencell , the ... it has seen a third consecutive year of triple ... technology in 2016 with a 360 percent increase in ... This increase was driven by sales of its wrist ... interest in its technology for hearables for fitness and ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... ... 2017 , ... DaVita Clinical Research (DCR), a ... device development, and Prism Clinical Research , a leader in providing fully ... Clinical Trials (VCT) has been selected by both companies as an exclusive ...
(Date:1/18/2017)... Portland, OR (PRWEB) , ... January 18, 2017 ... ... modules that provide essential device-to-computer interconnect using USB or PCI Express, announced the ... Altera Cyclone V E FPGA into a compact business-card sized form factor suitable ...
(Date:1/18/2017)... ... January 18, 2017 , ... Executive ... 2017 in its continued commitment to the advancement of the clinical trials segment. ... issues related to clinical trial planning and management. , As executive talent ...
(Date:1/18/2017)... , ... January 18, 2017 , ... Researchers from a new study are ... fall low enough after prostate cancer treatment, this indicates there is still remaining prostate cancer ... mortality. , “ The PSA test has always been an indicator of whether a man’s ...
Breaking Biology Technology:
Cached News: